Administration costs of intravenous biologic drugs for rheumatoid arthritis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://link.springer.com/content/pdf/10.1186/2193-1801-2-531.pdf
Reference37 articles.
1. Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, Ramirez-Arellano A, Dupont D: Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam 2011, 2011: 727634.
2. Bodger K, Kikuchi T, Hughes D: Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009, 30: 265-274. 10.1111/j.1365-2036.2009.04033.x
3. Chen Y-F, Jobanputra P, Barton P, et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006, 10: 1-229.
4. Cummins E, Asseburg C, Punekar YS, et al.: Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health 2011, 14: 15-23. 10.1016/j.jval.2010.10.016
5. Curtis L: Unit Costs of Health & Social Care 2011. Kent: Personal Social Services Research Unit; 2011.
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries;BMC Health Services Research;2022-11-04
2. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment;Inflammatory Bowel Diseases;2022-08-09
3. Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom;Applied Health Economics and Health Policy;2021-08-12
4. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis;Advances in Therapy;2019-12-23
5. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis;PLOS ONE;2019-07-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3